glp 1 neurological effects complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report | BMC Neurology Understanding GLP-1 receptor agonists and

Data from the STEP clinical trials demonstrate that diarrhoea and other digestive side effects typically diminish significantly after the first 3-6 months of treatment, even with continued medication use

These results indicate that exendin 939 does not share a binding site with CAP and inhibits TRPV1 activation by interacting noncompetitively with CAP

It may become available after regulatory reviews are completed

This perspective contrasts with failed targets , for which rigorous clinical evaluation has demonstrated unacceptable on-target toxicity or lack of efficacy at therapeutically relevant exposures

USA 102 , 1686516869 (2005)

However, the review stresses that direct attribution of these effects to GLP-1R-mediated anti-inflammatory pathways remains to be conclusively demonstrated